



COUNTRY PROFILE

The Netherlands

EDCTP participation



The Netherlands in EDCTP

(2003-present)

The Netherlands in EDCTP: key figures

Since 2003, institutions based in the Netherlands have played a major role in EDCTP-funded research, with broad participation, strong coordination roles, and extensive international partnerships.



146

projects involving institutions based in the Netherlands



34

Netherlands-based **institutions involved** in EDCTP-funded projects



63

collaborating countries with Netherlands-based institutions through EDCTP-funded projects



47

consortia-based **projects coordinated** by Netherlands-based institutions



€58.6 M

EDCTP funding attributed to Netherlands-based entities



420

international partner institutions collaborating with Netherlands-based entities*


M = million

*Distinct non-Netherlands-based institutions participating in EDCTP-funded projects that include at least one Netherlands-based entity

The Netherlands in EDCTP: participation over time

Since 2003, institutions based in the Netherlands have expanded their EDCTP participation, with high activity sustained into Global Health EDCTP3.

Participation of Netherlands-based institutions across EDCTP iterations




TMA = Training and Mobility Action; RIA = Research and Innovation Action; CSA = Coordination and Support Action. EDCTP 1 used 10 original funding categories, which were regrouped here under TMA, RIA and CSA equivalents for over-time comparability. In Global Health EDCTP3, CSAs may include fellowship components, but not direct individual fellowship grants as under the TMA model in EDCTP1 and 2.

The Netherlands in EDCTP: participating organisations

Since 2003, institutions based in the Netherlands have contributed through a broad research ecosystem, spanning universities, medical centres, and specialised global-health organisations.

Netherlands-based institutions by EDCTP funding




The Netherlands in EDCTP: international collaboration

Since 2003, institutions based in the Netherlands have built one of EDCTP’s broadest collaboration networks, strongly connecting Europe and Africa.

63 collaborating countries: **38** in Africa | **17** in Europe | **8** in other regions

Top 20 partner countries by number of collaborating Netherlands-based institutions



Geographical spread of the Netherlands’ EDCTP collaboration links



The Netherlands in EDCTP: country rankings

Across the full period since 2003, the Netherlands ranks 8th in EDCTP funding attributed to participating entities and 9th in number of participating organisations.

Top 20 countries by EDCTP grant amount

Country	Value	Rank
South Africa	€ 216.9 M	1
United Kingdom	€ 184.6 M	2
Uganda	€ 111.2 M	3
United Republic of Tanzania	€ 95.1 M	4
Kenya	€ 84.1 M	5
Germany	€ 74.5 M	6
France	€ 73.4 M	7
Netherlands	€ 58.6 M	8
Spain	€ 58.3 M	9
Burkina Faso	€ 51.3 M	10
Mozambique	€ 49.8 M	11
Switzerland	€ 44.3 M	12
Zambia	€ 42.7 M	13
Ghana	€ 42.3 M	14
Mali	€ 38.0 M	15
Senegal	€ 35.4 M	16
Gabon	€ 33.0 M	17
Ethiopia	€ 32.0 M	18
Democratic Republic of the Congo	€ 32.0 M	19
Belgium	€ 30.1 M	20

Top 20 countries by number of participating organisations

Country	Value	Rank
United Kingdom	57	1
France	50	2
South Africa	50	2
Uganda	48	3
Spain	43	4
Kenya	42	5
Germany	37	6
Nigeria	36	7
Netherlands	34	8
Italy	33	9
United Republic of Tanzania	31	10
Ethiopia	29	11
Switzerland	25	12
United States	24	13
Cameroon	19	14
Rwanda	18	15
Belgium	17	16
Burkina Faso	16	17
Ghana	16	17
Democratic Republic of the Congo	15	18

The Netherlands' wider contribution to EDCTP

Beyond project participation, the Netherlands has supported EDCTP through financial contributions and national in-kind activities aligned with programme objectives.

€734.2 K in-cash contribution

The Netherlands' contribution to the EDCTP Association (2015-2022)

€73.7 M aligned in-kind investments

Value of the Netherlands' national in-kind activities aligned with EDCTP Programme objectives (2014-2024)

Aligned in-kind activities

Dutch Investment in Product Development Partnerships (PDPs)

- **Dutch commitment to global health innovation:** The Netherlands' Global Health Strategy underpins a dedicated PDP funding scheme to advance simpler, more effective, and affordable health products for poverty-related and neglected diseases and sexual and reproductive health, prioritising women and girls in LMICs.
- **Alignment with EDCTP:** The scheme fully aligns with EDCTP's objectives and disease scope, promoting open research data and equitable access to affordable health innovations.
- **Sustained investment:** Over €80 million allocated since 2022, including €30 million co-invested through the IV PDP funding round launched in 2025, reflecting the Netherlands' sustained commitment to global health innovation.

Impact example: expanding malaria treatment options with Pyramax®

Through PYRAPREG and PYRAPREG-extended projects, Netherlands-based organisations helped strengthen the evidence base for Pyramax® use in pregnancy.

Story

Pyramax® is an established antimalarial treatment whose use has been progressively expanded through EDCTP-supported research. Netherlands-based organisations were involved in the original PYRAPREG project, and Amsterdam UMC coordinated PYRAPREG-extended, completing follow-up and data analysis on pyronaridine-artesunate use in pregnancy.

What changed

After an EMA positive scientific opinion in 2012, EDCTP-supported studies helped address remaining evidence gaps: safe and effective re-treatment, information on use in pregnancy, and a paediatric formulation for children needing age-appropriate treatment.

Why this matters

Malaria still causes major illness and death in Africa, especially among young children. Pregnant women and children are often under-represented in clinical research, so better evidence can support safer treatment decisions for groups with limited options.

EDCTP's contribution included:

- ✓ supporting clinical research that broadened evidence on Pyramax® for re-treatment, children, and pregnant women
- ✓ supporting follow-up, data analysis, and pharmacokinetic studies to inform malaria treatment decisions in pregnancy.

[*More info here*](#)



Impact example: improving HIV treatment for children

Through successive CHAPAS studies, Netherlands-based institutions have contributed to long-term research improving child-friendly HIV treatment options.

Story

For more than 20 years, EDCTP has supported CHAPAS research to identify safer, more effective, and child-friendly HIV treatment options. Netherlands-based participation included Radboud University Nijmegen Medical Centre in CHAPAS-1 and CHAPAS-3, Stichting Katholieke Universiteit - Radboudumc in CHAPAS-4, and Stichting Radboud Universitair Medisch Centrum in CHAPAS-5.

What changed

CHAPAS research contributed to the registration of **Triomune Baby/Junior** in 2007, the first fixed-dose combination medicine developed specifically for children with HIV. Later studies informed WHO recommendations, and CHAPAS-4 announced a new paediatric ART regimen in 2025 that improves viral suppression and is easier to administer.

Why this matters

Children with HIV still face major treatment gaps: only around half receive treatment, and unsuitable formulations can undermine adherence. Better child-friendly treatment options can help reduce preventable illness and deaths and improve long-term care.

EDCTP's contribution included:

- ✓ supporting long-term CHAPAS research on safer, more effective and child-friendly HIV treatment options
- ✓ supporting continued innovation through CHAPAS-5, an adaptive clinical trial platform evaluating new antiretroviral treatments for children and adolescents.

[*More info here*](#)



EDCTP project highlight

The Netherlands has been actively involved in PanACEA2, an EDCTP-funded tuberculosis drug-development consortium.

PanACEA2 was led by Professor Martin Boeree at Radboud University Nijmegen Medical Centre in the Netherlands, bringing together partners from Europe and six African countries. EDCTP awarded the project €11.4 million in 2018.

Building on the earlier PanACEA programme, the consortium aims to develop shorter, simpler, and better TB treatments, including studies of higher doses of rifampicin and promising new drugs and drug combinations.

PanACEA2 also pioneers innovative and adaptive clinical-trial designs to identify promising regimens more efficiently, reduce the risk of failure in costly phase III trials, and strengthen African capacity to conduct TB trials to the highest international regulatory standards.



EDCTP project highlight

The Netherlands led PAVIA, strengthening pharmacovigilance systems in four African countries.

The PAVIA project was led by the Amsterdam Institute for Global Health and Development (AIGHD). It strengthened national systems for monitoring the safety of medicines, initially focusing on the introduction of new treatments for multidrug-resistant tuberculosis.

The project worked in Ethiopia, Eswatini, Nigeria and Tanzania, strengthening collaboration between national regulatory authorities, public-health programmes, and research institutions, while developing training and practical tools for pharmacovigilance.

PAVIA helped Eswatini develop and implement its first standalone national pharmacovigilance policy, and produced a blueprint for strengthening systems in resource-limited settings, allowing lessons from the project to be applied more widely.

EDCTP contribution: €3 million, within a total project value of €12.8 million.




The Netherlands in Global Health EDCTP3

(2021-present)

The Netherlands in Global Health EDCTP3: key figures

Since 2021, Netherlands-based institutions have combined high project participation, strong coordination roles, and broad international partnerships, making them key contributors to Global Health EDCTP3.


- 58**
Funded **projects** with Netherlands-based organisations
- 34**
Projects **coordinated** by Netherlands-based organisations
- 18**
Netherlands-based **organisations** participating in funded projects
- 50**
countries collaborating with Netherlands-based organisations
- 9**
Dutch **experts** who evaluated project proposals
- €25.1 M**
Grant **funding** attributed to Netherlands-based organisations




The Netherlands in Global Health EDCTP3: participating organisations

Since 2021, institutions based in the Netherlands have contributed through a diverse mix of organisations, led by specialised global-health actors and university medical centres.

Netherlands-based participating organisations by type




Netherlands-based participating organisations by grant amounts



The Netherlands in Global Health EDCTP3: international network

Since 2021, institutions based in the Netherlands have collaborated with partners in 50 countries, with particularly strong links across Africa and Europe.

Top 15 collaborating countries with Netherlands-based institutions in funded projects (number of links)



Geographical distribution of the Netherlands' collaboration links



Governance and advisory input

Since 2021, Netherlands-linked representation has included both formal programme oversight and stakeholder advice.

ADVISORY

Netherlands-linked representatives
in the Stakeholders' Group

European Global Health
Research Institutes Network,
EGHRIN

Ana Barroso Abecasis
Representative

Sara M. Soto
Alternate

GOVERNANCE

Representation of the Netherlands in EDCTP
Association decision-making body

Sarah Spronk

General Assembly

Ministry of Foreign Affairs

The EDCTP Association has its registered office in The Hague.



2014



The Netherlands became a
member of the EDCTP Association

Project highlight: SMV delivery

A Netherlands-based medical centre coordinates research on how best to deliver malaria vaccine booster doses to children in areas with seasonal transmission.

The challenge:

- Current malaria vaccine protection fades over time.
- The best timing and way to provide booster doses in seasonal malaria areas is still unclear.

Expected impact:

- Compare three malaria vaccine booster delivery strategies in Guinea and Mali, assessing coverage and impact on malaria cases:
 - Age-based delivery via routine clinics,
 - Seasonal delivery via routine clinics,
 - Seasonal delivery via community mass campaigns.



Coordinator:

Stichting Radboud universitair medisch centrum,
Netherlands

Scientific leader:

**Université des Sciences, des Techniques et des
Technologies de Bamako, Mali**

Countries: **Netherlands, Guinea, Mali, Spain, UK**

Funding: **€4,352,355**

Project length: **2024 – 2028**

<https://www.smv-delivery.com/index.php/en>

SMV delivery - Global Health EDCTP3 - European Union

Project highlight: SAFIRE

A Netherlands-based medical centre coordinates a clinical trial platform to evaluate antimalarial treatments for women in early pregnancy.

The challenge:

- Pregnant women are highly vulnerable to malaria but cannot safely receive most preventive treatments.
- This causes very few antimalarial drugs to be recommended in early pregnancy.

Expected impact:

- Deliver high-quality safety and efficacy data on newer ACTs, starting with comparing pyronaridine-artesunate in women in the first trimester of pregnancy.
- Engage stakeholders on trial design and communities to build support and ensure policy impact.



Coordinator:

Stichting Amsterdam UMC, Netherlands

Scientific leader:

Kenya Medical Research Institute, Kenya

Countries: **Netherlands, Kenya, Mali, Burkina Faso, DRC, Uganda, Switzerland, UK**

Funding: **€5,191,431.44**

Project length: **2024 – 2028**

<https://safire-consortium.org/>

SAFIRE - Global Health EDCTP3 - European Union

Project highlight: PROTID

A Netherlands-based medical centre coordinates research assessing whether TB preventive treatment can reduce disease burden among people living with type 2 diabetes.

The challenge:

- Type 2 diabetes increases the risk of TB illness and death.
- Undiagnosed TB fuels transmission, especially among high-risk groups like people with diabetes.

Expected impact:

- Complete screening and data analysis to assess whether preventive TB treatment reduces disease burden in people with type 2 diabetes.
- Identify an optimal type 2 diabetes care pathway.
- Provide policymakers with evidence on the impact and cost-effectiveness of the treatment.



Coordinator:

Stichting Radboud universitair medisch centrum,
Netherlands

Scientific leader:

National Institute for Medical Research, Tanzania

Countries: **Netherlands, Tanzania, Uganda, New Zealand, UK**

Funding: **€2,337,586.25**

Project length: **2024 – 2026**

<https://protid-africa.com/>

[PROTID - Global Health EDCTP3 - European Union](#)

Project highlight: PEP4LEP 2.0

A Netherlands-based leprosy organisation coordinates research comparing community- and facility-based delivery of post-exposure prophylaxis for leprosy.

The challenge:

- Leprosy causes disability and stigma in sub-Saharan Africa.
- Limited dermatology specialists and high skin disease burden call for integrated primary care approaches.

Expected impact:

- Detect leprosy and other skin conditions in Ethiopia, Mozambique, and Tanzania, providing PEP as needed.
- Compare the effectiveness and cost-effectiveness of PEP delivery via 'skin camps' versus in health facilities.



Coordinator:

Nederlandse Stichting voor Leprabestrijding,
Netherlands

Scientific leader:

Armauer Hansen Research Institute, Ethiopia

Countries: **Netherlands, Ethiopia, Germany,**
Mozambique, Tanzania

Funding: **€1,780,303.75**

Project length: **2024 – 2026**

PEP4LEP 2.0 - Global Health EDCTP3 - European Union

PEP4LEP

Project highlight: ACTTIVAC

A Netherlands-based vaccine initiative coordinates a Phase 2a trial of a thermostable tuberculosis vaccine candidate.

The challenge:

- TB remains a major global health challenge.
- Developing effective tuberculosis vaccines is challenging due to limited understanding of protective immunity and a high risk of candidate failure.

Expected impact:

- Conduct a Phase 2a trial of the thermostable ID93+GLA-SE tuberculosis vaccine to assess safety, immune responses, and optimal dosing.
- Transfer vaccine manufacturing technology to African partners to strengthen local production capacity.



Coordinator:
Stichting Tuberculosis Vaccine Initiative,
Netherlands

Scientific leader:
University of Cape Town, South Africa

Countries: **Netherlands, South Africa, UK,**
Nigeria

Funding: **€11,943,468.75**

Project length: **2026 – 2030**

ACTTIVAC - Global Health EDCTP3 - European Union

Project highlight: SINCEP-Africa

The Netherlands-based EDCTP Association coordinates SINCEP-Africa to strengthen a trial-ready research network for epidemic response in sub-Saharan Africa.

The challenge:

- Limited clinical trial readiness and rapid outbreak-response capacity in sub-Saharan Africa.
- Need for stronger infrastructure, trained staff, and coordinated research networks across multiple sites.

Expected impact:

- Strengthen 16 African research sites through training, infrastructure upgrades and laboratory improvements.
- Deploy an AI-powered surveillance and data-sharing system to improve outbreak detection and response.
- Establish a trial-ready network able to rapidly launch clinical studies during disease outbreaks.



Coordinator:
European & Developing Countries Clinical Trials Partnership, Netherlands

Scientific leader:
INDEPTH Network, Ghana

Countries: **Netherlands, Ghana, United Kingdom, France, Côte d'Ivoire, Burkina Faso, DRC, Mali, Mozambique, Tanzania, Kenya, Uganda, Spain, United States, Ethiopia, Nigeria, Senegal**

Funding: **€13,366,351**

Project length: **2026 – 2031**

SINCEP-Africa - Global Health EDCTP3 - European Union





Global Health
EDCTP3



EDCTP

Thank you!

Global Health EDCTP3



Co-funded by
the European Union

